EP0912519A1 — Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors

USPTO Abstract

A compound of general formula (i), wherein R is H, halogen or alkyl; R1 represents OH, alkoxy optionally substituted with one or more halogens, or thioalkyl; R2, R3 and R4 are the same or different and are each H, R7, OR11, COR7, C(=NOR7)R7, alkyl-C(=NOR7)R7, alkyl-C(=NOH)R7, C(=NOH)R7, halogen, CF3, CN, CO2H, CO2R11, CONH2, CONHR7, CON(R7)2, NR9R10 or CONR12R13 where NR12R13 is a heterocyclic ring optionally substituted with one or more R15; R5 represents H, arylalkyl, heteroarylalkyl, S(O)mR11 or alkyl optionally substituted with one or more substituents chosen from hydroxy, alkoxy, CO2R8, SO2NR12R13, CONR12R13, CN, carbonyl oxygen, NR9R10, COR11 and S(O)nR11; R6 represents aryl, heteroaryl, arylalkyl or heteroarylalkyl. The compounds can be used to treat disease states, for example disease states associated with proteins that mediate cellular activity, for example by inhibiting tumour necrosis factor and/or by inhibiting phosphodiesterase IV.